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ScienceDirectImmunotherapies are yielding effective treatments for several
previously untreatable cancers. Until recently, vaccines and
adoptive cell therapies have been designed to target public
tumor antigens common to multiple patients rather than private
antigens specific to a single patient. Due to the difficulty of
identifying public antigens that are expressed exclusively on
tumor cells, these studies have yielded both clinical successes
and serious immune-related adverse events. Multiple avenues
of research now underscore the centrality of tumor-specific
mutated private antigens to endogenous anti-tumor immunity.
Immunotherapies that target these neoantigens may enable
safer and more durable tumor regression, but personalized
targeting presents a number of challenges. Foremost among
these is to develop processes that accelerate advancement
from neoantigen discovery to use of these neoantigens as
vaccines or as targets for adoptive cell therapies. Exome
sequencing has facilitated discovery of neoantigens for
melanoma and other highly mutated cancers. New
technologies – possibly proceeding from T cell receptor
repertoire sequencing – are needed to identify antigens for
cancers with low mutational burden and few neoantigens. In
this review, we discuss progress toward personalizing T cell-
mediated immunotherapy for cancer as well as challenges
going forward.
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Immunotherapy: a new paradigm for cancer
treatment
The field of cancer immunology grew from tumor trans-
plantation studies in syngeneic mice [1]. These studies
(reviewed in Ref. [2]) provided evidence for theCurrent Opinion in Biotechnology 2017, 48:142–152 immunosurveillance hypothesis, which posited that
tumors express ‘new antigenic potentialities’ arising from
somatic mutation and that these antigens are specifically
targeted by the immune system [3]. Concurrently, clin-
icians observed that lymphocytic infiltration into resected
carcinomas correlated with longer post-operative survival
for human patients [4]. Subsequent attempts to mobilize
anti-tumor immunity through vaccination generally
failed, however, and surgery, radiotherapy, and chemo-
therapy remained the mainstays of cancer treatment for
the majority of the twentieth century [5].
Three avenues of research revitalized interest in cancer
immunotherapy, particularly as mediated by T lympho-
cytes. First, the role of T cells in tumor immunity was
cemented by the observation that mice deficient for
lymphocytes (RAG2/) or for T cell effector molecules
(perforin and interferon-g) exhibited a higher incidence
of spontaneous carcinoma [6,7]. Second, clinical
interventions that boosted T cell responses – either
through infusion of interleukin-2 (IL-2) or through adop-
tive transfer of autologous tumor-infiltrating lymphocytes
(TILs) – resulted in tumor regression in a subset of
patients with metastatic melanoma [8–11,12]. Third,
interventions that relieved suppression of T cell
responses – most notably antibody-mediated blockade
of the checkpoint receptors cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) and programmed cell
death protein 1 (PD-1) – resulted in durable tumor
regression in mice and humans [13,14,15]. It is now
established that endogenous T cells can recognize and
kill cancer cells. Cancer immunotherapies exploiting this
capacity constitute a paradigm shift in cancer treatment,
yielding successes where conventional cancer therapies
fail [16]. Recent advances in this rapidly moving field are
focused on characterizing the antigens targeted by anti-
tumor immunity and learning from these how to design
immunotherapies of greatest clinical benefit.
Focus shifts from public to private antigen
targeting
A unique T cell receptor (TCR) expressed on each T cell
enables the cell to scan for antigens presented on major
histocompatibility complex (MHC) molecules on the
tumor cell surface. Broadly, these tumor antigens are of
two types: (1) non-mutated public antigens, including
tissue-specific or cancer-testis (CT) antigens that are
aberrantly expressed in cancerous cells; and (2) private
neoantigens resulting from non-synonymous somatic
mutations within the cancerous cells [17]. Public antigenswww.sciencedirect.com
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expressed on normal tissues, whereas neoantigens are
tumor-specific but generally also patient-specific [18,19].
Due to the clearer path to clinical application, targeted
immunotherapies have predominantly focused on public
antigens. Therapeutic vaccines designed to stimulate T
cell responses to public antigens have yielded modest
success (e.g., sipuleucel-T was approved for treatment of
metastatic castration-resistant prostate cancer in
2010 [20]). However, vaccination with public antigens
has not generally worked well, likely because T cells
specific for such antigens are either absent or functionally
suppressed by the tumor microenvironment [5]. TCR
gene therapy is a more effective means of targeting
specific public antigens. Because the TCR is the sole
determinant of T cell specificity [21], viral transfer of
genes encoding a public antigen-specific TCR can impart
tumor reactivity to autologous peripheral T cells [22].
Following expansion and re-infusion, these engineered T
cells specifically kill those cells presenting their cognate
(targeted) antigen. TCR gene therapy has achieved
objective response rates of 13–67% for multiple cancer
types – most notably melanoma and synovial cell carci-
noma – by targeting the melanocyte differentiation anti-
gen, MART-1/Melan-A, or the CT antigen, NY-ESO-1,
respectively [23,24,25,26].
Notwithstanding these successes, targeting public anti-
gens presents safety and efficacy concerns. Public anti-
gens are often tumor-associated rather than truly tumor-
specific in their expression. As such, targeting them can
result in on-target but off-tumor reactivity [27]. Public
antigen-specific TCRs have low affinity for their non-
mutated targets due to central tolerance and attempts to
evolve higher affinity TCR variants can introduce cross-Table 1
Select examples of adverse events resulting from clinical application 
Antigen Immunotherapy Adverse ev
MART-1/MelanA TCR Fatal neural and cardiac 
Uveitis, Hearing loss, Loss
TCR + DC vaccination Acute respiratory distress
NY-ESO-1 TCR (Affinity enhanced) Skin rash with lymphocyt
syndrome
MAGE-A3 TCR (Affinity enhanced) Fatal cardiogenic shock 
TCR (Affinity enhanced) Mental status changes, c
necrotizing leukoencepha
extensive white matter d
www.sciencedirect.com reactivity that is difficult to predict [28,29]. Consequences
of off-tumor reactivity range from manageable morbidity
to serious adverse events and even death (Table 1)
[24,28,30–33].
Due in part to these challenges and in part to the advent
of deep-sequencing technologies, there has been a recent
surge in interest in targeting patient-specific neoantigens.
Because these antigens occur only within tumor tissue,
they are not presented by thymic epithelial cells and do
not induce central tolerance. Therefore, neoantigen-spe-
cific TCRs may be both more specific and higher affinity
than TCRs targeted to public antigens. It is also becom-
ing increasingly clear that – at least for tumors with high
mutational burden – neoantigens are important targets of
endogenous immunity. Mutated neoantigens contribute
to tumor recognition by TILs [34]. Adoptive TIL
therapy is generally well-tolerated and achieves up to
72% objective responses for metastatic melanoma [35],
suggesting this targeting is clinically relevant. Moreover,
adoptive transfer of TILs specific for a single neoantigen
is sufficient to mediate tumor regression [36]. Check-
point blockade trials similarly indicate that neoantigens
are central to anti-tumor immunity. In melanoma, the
tumor mutational burden and number of predicted
neoantigens correlate with clinical response to ipilimu-
mab (anti-CTLA-4) [37,38]. High tumor mutational bur-
den is a prognostic biomarker for PD-1 blockade as well,
predictive of higher response rates for non-small cell lung
cancer (NSCLC) [39] and mismatch repair-deficient
colorectal carcinoma [40]. Tumors with many shared
(truncal) mutations express high levels of the ligand for
PD-1 and respond particularly well to checkpoint block-
ade [41]. Collectively, these results suggest that neoanti-
gens are targets of endogenous immunity and may be
ideal targets for cancer immunotherapy.of immunotherapies targeting public antigens
ent Cause Ref.
toxicity High levels of inflammatory cytokines
alone or in combination with semi-acute
heart failure and epileptic seizure
[30]
 of pigmentation On-target activity of TCR-engineered T
cells targeting normal cells expressing the
cognate epitope
[24]
 High levels of inflammatory cytokines [31]
osis, diarrheal Autologous GVHD-like syndrome possibly
due to loss of self-tolerance
[32]
Cross-reactivity with an unrelated epitope
from the Titin protein presented on cardiac
tissue
[28]
omas,
lopathy with
efects
Reactivity to similar MAGE-A12-derived
epitope presented on neural cells
[33]
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immunotherapies
Checkpoint blockade mobilizes endogenous T cells by
breaking tolerance to self-antigens, including but not
limited to neoantigens. While this approach achieves
remarkably durable tumor regression in a subset of
patients, there are limitations. For example, tumor-resi-
dent effector cells mobilized by checkpoint blockade can
possess stable epigenetic markers of exhaustion, hamper-
ing their ability to form memory cells [42]. Additionally,
broadly breaking self-tolerance results in adverse events
in over 50% of patients when multiple checkpoints are
inhibited [43]. By contrast, effector cells used in adoptive
therapies can be selected or engineered for optimal
phenotype and targeted specifically to neoantigens.
Thus, personalized T cell-mediated immunotherapies
may be more effective and engender less morbidity than
checkpoint blockade, provided we can overcome the
challenges of personalization.
There is a degree of personalization intrinsic to T cell-
mediated cancer immunotherapies. Public antigens are
expressed heterogeneously across cancers, among
patients with the same cancer, and even among an indi-
vidual patient’s cancer cells. Additionally, MHCFigure 1
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Current Opinion in Biotechnology 2017, 48:142–152 restriction limits the pool of patients who are candidates
for treatment with any given TCR. Finally, adoptive TIL
therapy, TCR gene therapy, and dendritic cell-based
vaccines already require laborious manipulation of autol-
ogous cells. Nonetheless, targeting neoantigens on a
patient-by-patient basis presents unique challenges of
both scientific and logistic nature. These include accel-
erating antigen and receptor discovery, devising alternate
discovery strategies for cancers with few neoantigens, and
improving response rate and durability, all while negoti-
ating new regulations necessary for safe implementation.
Neoantigen discovery
A neoantigen is formed only when somatic mutation
creates a peptide epitope that is expressed, processed,
presented by one of the patient’s MHC molecules, and
recognized by a subset within the patient’s T cell reper-
toire (Figure 1). This stochastic outcome has been com-
pared to a lottery in which each mutation increases the
odds of neoantigen formation [44]. Most mutations do not
create neoantigens and those that do are generally
bystander mutations that are incidental to cancer progres-
sion and unique to each responding patient [38,45,46].
Thus, high-throughput methods are required to identifyF EQ
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that bind self-peptides presented on self-MHC are deleted during
xpressed genes. They are immunogenic because they are not
f a TCR-facing residue results in a previously tolerated self-peptide
 previously unpresented and untolerated self-peptide binding to a
epicted are derived from human b-actin (ACTB) protein. Predicted
ulated using NetMHC 4.0 [48,49].
www.sciencedirect.com
Personalized T cell-mediated cancer immunotherapy Bethune and Joglekar 145the subset of patient-specific mutations that result in
neoantigen formation.
The first molecular identification of a neoantigen was
achieved by Boon et al., who used laborious expression
cloning to identify a single mutation responsible for
tumor rejection by cytotoxic T cells from syngeneic mice
[47]. Modern neoantigen discovery studies use a ‘reverse
immunology’ approach, identifying hundreds of patient-
specific mutations by deep-sequencing the exome from
resected tumor tissue and comparing these data to refer-
ence data from normal tissue. MHC class I-restricted
neoantigens arising from these mutated peptide
sequences are predicted using algorithms that calculate
the affinity of derived mutant peptides for MHC-I alleles
relevant to the patient [48–50]. These putative neoanti-
gens are then validated by testing for recognition by
CD8+ T cells (e.g., using MHC-I multimers or peptide-
pulsed presenting cells). Following demonstration in
mouse models [51,52], this approach was first applied
to human clinical samples to identify neoantigens tar-
geted by adoptive TIL therapy and checkpoint blockade
in patients treated for melanoma [34,53]. Exome-
guided discovery has revealed that melanoma-infiltrating
T cells frequently respond to MHC class II-restricted
neoantigens as well [45]. Because epitope prediction and
tetramer production are challenging for MHC class II
epitopes, this was demonstrated by pulsing autologous
cells with peptides comprising all mutations identified
through exome sequencing and then determining which
of these elicit CD4+ T cell reactivity [45]. Finally,
neoantigens can be identified directly from tumor-
derived MHC eluates using mass spectrometry
[54,55,56,57], provided its sensitivity can be made
comparable to immunological methods. This approach
may be particularly well-suited to detecting neoantigens
arising from aberrant splicing, cryptic start sites, or post-
translational modifications, none of which would be evi-
dent from exome sequencing [57,58,59].
Targeting neoantigens directly through vaccination or
tailored adoptive TIL therapy
Once identified, neoantigens can be used diagnostically
(e.g., as biomarkers to characterize and monitor T cell
responses to checkpoint blockade) or therapeutically (e.g.,
as targets for therapeutic vaccines or adoptive cell thera-
pies). The most straightforward means of targeting
neoantigens is through therapeutic vaccination. Mice
injected with dendritic cell vaccines incorporating long
peptide neoantigens induced tumor rejection comparable
to checkpoint blockade [54]. Importantly, clinical appli-
cation of neoantigen vaccination induced expansion of
neoantigen-specific T cells without impacting disease
progression [56], suggesting vaccination may be best
employed as an adjunct to adoptive cell therapy or
checkpoint blockade.www.sciencedirect.com Personalized adoptive T cell therapies require the selec-
tive expansion or capture of neoantigen-specific T cells.
This has been achieved with various technologies. Schu-
macher et al. pioneered the use of UV-induced peptide
exchange to enable rapid assembly of peptide-MHC
multimer libraries [60]. Combined with multi-color
encoding and fluorescence-activated cell sorting [61],
these libraries enable the isolation of neoantigen-specific
T cells from TILs and peripheral blood [53,62]. A varia-
tion of this approach employs UV-exchanged peptide-
MHC multimers labeled with DNA barcodes rather than
fluorochromes to capture neoantigen-specific T cells in a
spatially-encoded manner on a DNA-spotted microfluidic
device [63] (and unpublished results). Alternately, Rosen-
berg and colleagues have demonstrated that neoantigen-
specific T cells can be expanded from TILs and blood
using autologous presenting cells expressing tandem
neoantigen minigenes [64,65].
A critical question facing the field is how to employ
neoantigen-specific T cells on a clinically useful time-
scale while navigating a novel regulatory landscape.
Adoptive therapy with TILs of undefined composition
achieves durable tumor regression in 20% of melanoma
patients [66]. It may be possible to improve this response
rate by enriching for neoantigen-reactive T cells prior to
infusion (e.g., based on antigenic specificity or surface
expression of PD-1) [36,67,68,69,70]. Such person-
ally tailored adoptive TIL therapies – which provide
direct evidence for the clinical relevance of neoanti-
gen-specific TILs – have several attractive features. First,
there are indications that the proportion of TILs that are
neoantigen-specific may affect clinical efficacy
[68,69], though this has not been rigorously demon-
strated. Second, production of tailored cell products
requires only marginally more labor and turn-around time
than is already required for on-demand preparation of
unsorted TILs. Indeed, tumor-reactive TILs can be
selected based on expression of activation markers such
as PD-1 or CD137 even without identifying their cognate
epitopes [69,70]. Third, regulatory approval may be
more readily granted for enrichment for pre-existing
specificities than for introduction of new specificities
through TCR gene transfer [71], particularly when target-
ing multiple neoantigens. Indeed, both monoclonal and
polyclonal tailored TIL products have been administered
to patients already [36,68].
Personalized TCR gene therapy
The alternative to tailored adoptive TIL therapy is to
clone TCR genes from neoantigen-reactive T cells for
heterologous expression in a distinct population of effec-
tor cells. While more laborious and likely more challeng-
ing from a regulatory standpoint, personalized TCR gene
therapy provides greater customizability and potentially
better efficacy than adoptive TIL therapy (Figure 2).Current Opinion in Biotechnology 2017, 48:142–152
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Figure 2
Current Personalization
Target Target
Prospective Personalization
TCR TCR
Effectors Effectors
Public Antigen (Off-the-shelf) Private Antigen (On demand)
Antigen-specific TCR (Off-the-shelf)
T cells (Off-the-shelf)
Neoantigen-specific TCR (On demand)
• Well characterized
• No discovery phase
• Toxicity assessment done
• Easier implementation
• Regulatory approvals such as IND ready
• Vector manufacturing established
• Autologous cell product
• Limited potential for engineering
• Product processing methods well-established
• Testing release criteria on the fly
• Newly identified
• Additional time required for neoantigen discovery
• Regulatory hurdles
• Need to obtain regulatory approvals
• Potentially unknown risks
• Newly discovered
• Additional time required for discovery
• Toxicity assessment required
• Tougher implementation
• Need to obtain regulatory approvals
• Need to manufacture new vector on a short timescale
• Heterologous cell product
• Can be engineered to have better efficacy
• Pre-manufactured and cryopreserved product
• Minimal processing before release
• Well-characterized
• No antigen discovery phase
• Fewer regulatory hurdles
• Risk relatively well-known  
T cells/HSCs (On demand)
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Comparison of the current state-of-the-art practice of TCR gene therapy with prospective modifications to enhance efficacy and facilitate
implementation.Adoptive TIL therapy requires surgical access to the
tumor to acquire TILs, and these fail to expand from
30% of resected melanoma samples [72]. By contrast,
neoantigen-reactive TCR genes can be captured from
patient peripheral blood [62,65] or even from T cells
from unrelated blood samples [73]. Unrelated donor
blood may in fact be a superior source of reactive TCRs,
because immunoediting promotes the loss of neoantigens
recognized by the autologous TCR repertoire during
tumor development [51,73,74]. In combination with
sequencing of circulating tumor cells or cell-free tumor
DNA, it is conceivable that identification of both neoanti-
gens and reactive receptors will be achievable from blood
in the future.
Personalized TCR gene therapy provides considerable
flexibility in terms of effector cell identity as well.
Whereas expansion of TILs for adoptive therapy can lead
to exhaustion, TCR gene transfer to naı¨ve peripheral T
cells or hematopoietic stem cells provides a large – even
continually renewable – supply of tumor-reactive T cells
of superior phenotype [75,76]. Recent advances in gene
editing and synthetic biology can further enhance the
potency and safety of engineered adoptive therapies byCurrent Opinion in Biotechnology 2017, 48:142–152 modulating expression of endogenous TCRs or
checkpoint receptors [77–80]. Notably, genome-edited
allogeneic T cells expressing chimeric antigen receptors
targeted to CD19 were employed recently as an off-
the-shelf immunotherapy [81]. Targeting neoantigens
precludes this degree of universality, but off-the-shelf
allogeneic effector cells transduced with patient-specific
TCR genes offer other advantages. For example, this
approach would simplify lot testing for the infused effec-
tor cell product. Moreover, this approach allows the use of
logical programming to limit off-tumor reactivity, prevent
escape, or impart novel effector functions on these engi-
neered cells [82–84]. Graft-vs-host disease is a prominent
risk of using allogeneic donor effector cells. Careful lot
testing to ensure extirpation of donor TCR and/or MHC
expression – possibly in combination with a fail-safe
mechanism to eradicate graft cells – will be necessary
to enhance safety of allogeneic effector cell grafts [81].
Expanding personalized T cell
immunotherapies to cancers with low
mutational burden
Mutational burden varies widely across tumor types
[85]. Many of the successful immunotherapy trialswww.sciencedirect.com
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ultraviolet- or carcinogen-induced tumors with high
mutational burden (>10 mutations/Mb). For tumors with
intermediate to low mutational burden (<1 mutation/
Mb), neoantigens are relatively rare and less likely to
be operative in eliciting anti-tumor immunity
(Figure 3). Nonetheless, TILs are present in such tumors
[36,86,87]. These include neoantigen-specific T cells
[36], but there are likely to be non-mutated antigens
recognized as well. Exome-guided approaches cannot
identify such targets, so antigen-agnostic alternatives
are needed to elaborate anti-tumor immunity for tumors
with low mutational burden.
One such strategy is to use a personalized TIL-guided
approach: isolate T cells mediating endogenous immu-
nity to a particular tumor and then use these cells or their
TCRs to identify those antigens that are driving the
immune response (Figure 3). Tumor-reactive T cells
infiltrate the tumor stroma, become enriched in this
context, and express PD-1 [69,88,89]. In multiple can-
cer types, single tumor-reactive clones constitute as much
as 25–50% of the TIL TCR repertoire and mediate tumor
regression following tailored TIL therapy [36,68].
High clonality and PD-1 expression on infiltrating cells
are also associated with clinical response to PD-1 block-
ade [90]. Thus, tumor-reactive T cells can be identified
from TILs based on their location, frequency, and/orFigure 3
High Mutational Burden Whole Exome
N.S. mutations
Expressed
Antigens
Neo
Antigens
Exome-Seq
RNA-Seq
MHC binding
prediction
Exome-guided discovery of neoantigens employs whole exome sequencing
filtering steps to identify those mutations likely to be immunogenic. Cancers
non-synonymous mutations, a subset of which will be immunogenic neoant
synonymous mutations may be 10–100-fold lower and neoantigens will be r
cancers may be to identify T cells mediating immunity (e.g., based on TIL T
cells. TCRs for which tumor reactivity is confirmed and MHC restriction can
Dashed arrows indicate process steps for which no high-throughput metho
www.sciencedirect.com phenotype without a priori knowledge of their antigenic
specificity.
Just as deep-sequencing technologies have enabled high-
throughput discovery of patient-specific neoantigens, so
too are they enabling comprehensive description of
patient-specific TCR repertoires. Specifically, it is now
possible to identify the frequencies of unique TCR
clonotypes among TILs [91]. Multiple technologies have
emerged to obtain paired TCRa and TCRb sequence
reads [63,92,93], facilitating functional cloning of the
most frequent TCR genes. The bottleneck for this
approach is that there are no high-throughput technolo-
gies for identifying the cognate antigens for these orphan
TCRs. A low-throughput approach has been described
that involves expressing the orphan TCR ectodomains as
a soluble, fluorescently-labeled reagent, and then using
this TCR reagent to selectively identify its cognate anti-
gen from a yeast cell surface-displayed peptide-MHC
library [94]. However, because soluble expression of
TCRs is laborious and non-robust, and MHC restriction
for a given TCR is difficult to predict, it will be challeng-
ing to scale this approach to identify antigens targeted by
multiple TCRs involved in a polyclonal immune
response. Ideally, TIL TCR specificity can be evaluated
in situ, for example by using TILs directly to capture or
mark those target cells expressing their cognate ligand
from among a cellular library expressing tumor-derived
cDNA.Low Mutational Burden TCR
Repertoire
Tumor
reactivity
MHC
Restriction
(Neo)antigen
Specificity
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 to identify non-synonymous mutations, followed by a number of
 with high mutational burden (>10 mutations/Mb) may have 100–200
igens. For cancers with low mutational burden, the number of non-
are or absent. An alternate approach for target discovery in these
CR frequency or expression of PD-1) and clone the TCRs from these
 be determined would then be used to capture their cognate ligands.
ds are yet available.
Current Opinion in Biotechnology 2017, 48:142–152
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Mutation drives the unchecked growth, heterogeneity,
and evolvability of cancer cells, rendering many cancers
refractory to conventional treatments. It is now clear that
mutation is also cancer’s Achilles’ heel, distinguishing it
from self and opening it to immunological attack. Per-
sonalized immunotherapies have scored stunning victo-
ries against cancer by exploiting this vulnerability. Even
so, we have only just sampled the potential for personally
tailored immunotherapies to yield more effective and
safer cancer treatments. More victories – and many chal-
lenges – are ahead.
We have highlighted here several key challenges related
to target discovery and therapeutic implementation. First,
while deep-sequencing technologies have enabled rapid
neoantigen identification, targeting these antigens with
gene therapy will require an equally efficient pipeline for
cloning TCR genes from reactive T cells. Notably,
neoantigen-reactive T cells present in blood must be
expanded ex vivo for weeks before they are detected
by current methods. This timescale may be incongruent
with therapeutic needs for rapidly progressing cancers.
Second, alternatives to exome-guided approaches are
needed to extend immunotherapy to cancers with few
mutations. Patient-specific analysis of the TIL repertoire
may be an effective starting point to interrogate the
antigenic targets of anti-tumor immune responses that
are not focused chiefly on neoantigens. To do this will
require high-throughput methods to capture ligands for
orphan T cells identified as tumor-reactive based on
frequency and/or phenotype. Importantly, developing
such technologies for low mutational burden cancers will
benefit efforts to ‘de-orphanize’ T cell responses in
pathologies unrelated to mutation (e.g., autoimmune
inflammatory diseases). Third, tumors can escape initially
effective T cell responses through myriad mechanisms
[68,95], suggesting combination of T cell therapies with
orthogonal treatments may be beneficial. Finally, cancer
immunotherapies are complex ‘drugs’ that employ the
immune system as the active ingredient against a com-
plex disease. The immune repertoire and cancer exome
in every patient are unique and mutable. Personalizing
the immune effectors used and the cancer antigens tar-
geted will require reconciling timescales of clinical need,
on-demand manufacturing, and regulatory compliance.
These challenges, by no means insurmountable, will
prompt advances leading to safer and more effective
cancer immunotherapies.
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